MedTrace Logo

Maintenance of Efficacy.

NCT00796601 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2018-11-29

No results posted yet for this study

Summary

The hypothesis of Study A6061054 is to demonstrate superiority of efficacy of esreboxetine at 3 and 6 months compared to placebo.

Conditions

  • Fibromyalgia

Interventions

DRUG

Esreboxetine

Film coated tablets (2, 6, 8, 10 mg esreboxetine), once daily for 6 months

DRUG

Placebo

Film coated tablets (0 mg esreboxetine), once daily for 6 months

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-01
Primary Completion
2010-05-01
Completion
2010-11-01

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00796601 on ClinicalTrials.gov